[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100449245":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":43,"locations":48,"responsibleParty":57,"collaborators":10,"id":59,"slug":10,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":10,"enrollmentInfo":68,"targetDuration":71,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":82,"overallStatus":51,"whyStopped":10,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"iOMEDICO AG","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ovarian cancer",null,"Female patients with high grade OC (advanced or metastatic epithelial ovarian, fallopian tube and primary peritoneal cancer):\n\n* with newly diagnosed FIGO stage IIb-IV OC who are starting systemic treatment, independent of the treatment intention (adjuvant\u002Fcurative or palliative) or\n* with recurrent\u002Frelapsed disease, who received any previous systemic anti-tumor treatment and who are now starting their systemic treatment for first recurrent\u002Frelapsed disease.",[13],"Other: Physician's choice according to patient's needs.",{"label":15,"type":10,"description":16,"interventionNames":17},"Endometrial cancer","Female patients with locally advanced and inoperable or metastatic EC (FIGO stage III-IV) who are starting systemic first-line therapy.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"OTHER","Physician's choice according to patient's needs.","Routine care as per site standard.",[15,9],[25,29,32,35,37,40],{"name":26,"affiliation":27,"role":28},"Thomas Decker, Prof.Dr.","Ravensburg","STUDY_CHAIR",{"name":30,"affiliation":31,"role":28},"Ingolf Juhasz-Böss, Prof.Dr.","Freiburg",{"name":33,"affiliation":34,"role":28},"Elmar Stickeler, Prof.Dr.","Aachen",{"name":36,"affiliation":31,"role":28},"Dirk Watermann, Prof.Dr.",{"name":38,"affiliation":39,"role":28},"Anja Welt, Dr.","Essen",{"name":41,"affiliation":42,"role":28},"Achim Wöckel, Prof.Dr.","Würzburg",[44],{"name":5,"role":45,"phone":46,"phoneExt":10,"email":47},"CONTACT","+49 761 15242-0","info@iomedico.com",[49],{"facility":50,"status":51,"city":52,"state":10,"zip":10,"country":53,"cosmosGeoPoint":10,"geoPoint":10,"contacts":54},"Multiple sites all over Germany","RECRUITING","Multiple Locations","Germany",[55],{"name":5,"role":45,"phone":56,"phoneExt":10,"email":47},"+49 761 152420",{"type":58,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100449245",false,"NCT05129969","Registry Platform Ovarian and Endometrial Cancer","SMARAGD - Clinical Research Platform on Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancer Treatment and Outcomes","SMARAGD","Inclusion Criteria:\n\n* Confirmed high grade OC (advanced or metastatic epithelial ovarian, fallopian tube and primary peritoneal cancer):\n\n  * patients with FIGO stage IIb-IV OC who are starting systemic treatment or\n  * patients with recurrent\u002Frelapsed disease, who received any previous systemic anti-tumor treatment and who are now starting systemic treatment for recurrent\u002Frelapsed disease.\n* Locally advanced and inoperable or metastatic EC (FIGO stage III-IV) who are starting systemic first-line therapy.\n* Signed and dated informed consent (IC):\n\n  * Patients participating in PRO module: IC before first therapy cycle\n  * Patients not participating in PRO module: IC no later than six weeks after start of first therapy cycle\n\nExclusion Criteria:\n\n* newly diagnosed early-stage OC (FIGO stage I-IIa)\n* Low grade mOC OR\n* Early-stage EC (FIGO stage I-II)","FEMALE","18 Years",{"count":69,"type":70},1975,"ESTIMATED","3 Years","OBSERVATIONAL","The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with advanced or metastatic ovarian cancer (OC) or advanced or metastatic endometrial cancer (EC) in Germany.",[75,76,77,78,79,80,81],"Ovarian Cancer","Endometrial Cancer","Ovary Neoplasm","Endometrial Neoplasms","Carcinoma, Ovarian","Carcinoma","Neoplasm, Ovarian",[83,84,85,53,86,87],"Registry","Health service research","Epidemiology","Palliative treatment","Palliative care","2026-01-26",{"date":90,"type":91},"2026-01-28","ACTUAL",{"date":93,"type":91},"2021-11-25",{"date":95,"type":70},"2030-12",{"name":5,"class":6},1]